Weight Loss Giants Going Head-to-Head; FDA OKs Omnipod GO; GLP-1 Drugs for Wolfram?

Eli Lilly plans to test its diabetes drug and weight loss treatment candidate tirzepatide (Mounjaro) in a head-to-head trial against Novo Nordisk’s semaglutide (Wegovy). (Endpoints News)

One extreme risk of semaglutide for weight loss: malnutrition. (New York Times)

The FDA cleared Omnipod GO, a tubeless, basal-only insulin pump for adult patients with type 2 diabetes typically using daily injections of long-acting insulin, said maker Insulet.

Missouri is slated to become the first state to ban gender-affirming care in adults. (NPR)

The Endocrine Society threw its support behind a new bill proposing a $35 cap on insulin for people with private insurance.

As part of a $1 billion deal, Eli Lilly is selling its hypoglycemic glucagon nasal spray Baqsimi to Amphastar Pharmaceuticals. (Reuters)

“I couldn’t bring myself to join in the applause surrounding Lilly’s announcement,” said Leemore S. Dafny, PhD, of Harvard University in Boston, in a New England Journal of Medicine perspective piece on the recent insulin price cuts.

Could GLP-1 receptor agonists help patients with the rare condition Wolfram syndrome? (Diabetologia)

A $4.1 million NIH grant was awarded to Children’s Hospital at Montefiore in New York to dive deeper into why kids develop type 2 diabetes.

Soda, lemonade, and other sugary drinks were linked with premature death in people with type 2 diabetes. (The BMJ)